Recruiting

Testing a new medication for severe asthma that isn't controlled by current treatments

Plain-English translation of NCT07532265 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase 2 clinical trial testing a new medication called (KN-002) for people with severe asthma that remains poorly controlled despite using strong, daily asthma controller medications. About 512 people will be randomly assigned to receive either the medication at one of three different doses or a placebo (a dummy pill with no active ingredient). The study will compare how well the medication works and how safe it is compared to placebo.

Many people with severe asthma continue to have symptoms and asthma attacks even when taking the strongest available controller medications. This trial is testing whether this new medication could offer better control for patients whose current treatments are not working well enough.

Do you qualify?

You likely qualify if…

you have had asthma diagnosed by a doctor for at least 12 months
you have been on a strong asthma controller regimen (medium to high dose inhaled corticosteroid plus long-acting beta-agonist) for at least 6 months, with a stable dose for at least 4 weeks
you have had at least one asthma attack or exacerbation in the past 12 months despite being on your current asthma medicines
you have uncontrolled asthma symptoms based on a standardized symptom score during screening visits
you are between 18 and 40 years old (or older, depending on weight requirements) and weigh at least 40 kilograms
you are willing to use birth control during the study and for 16 weeks after if you are a woman who could become pregnant

You likely don't qualify if…

you are a current smoker or have a significant smoking history (10 pack-years or more)
you have had a heart attack, stroke, or blood clots in the past 12 months
you have a history of blood clots or a genetic condition that increases your clot risk
you have active liver disease or abnormal liver function tests
you have a current respiratory tract infection that has not fully resolved

What participation looks like

If you qualify and are enrolled, you will be randomly assigned to take either the new medication or a placebo at one of several doses over the course of the study. You will have regular visits with the study team where they will check your asthma control, lung function, and overall health. You will need to use a digital device to track your asthma symptoms daily and practice proper inhaler technique. The study will last several months, with frequent check-ins to monitor how well the treatment is working and whether you experience any side effects.

AI-generated summary from trial data · Aug 3, 2026 · Not medical advice

Trial locations(14 sites)

United States

Research site, Lancaster, California

Research site, San Jose, California

Research site, Brandon, Florida

Research site, Miami, Florida

Research site, Tampa, Florida